stoxline Quote Chart Rank Option Currency Glossary
  
Taysha Gene Therapies, Inc. (TSHA)
2.29  -0.17 (-6.91%)    07-17 16:00
Open: 2.46
High: 2.46
Volume: 2,184,688
  
Pre. Close: 2.46
Low: 2.21
Market Cap: 461(M)
Technical analysis
2024-07-17 5:30:50 PM
Short term     
Mid term     
Targets 6-month :  3.93 1-year :  5.04
Resists First :  3.36 Second :  4.32
Pivot price 2.25
Supports First :  1.83 Second :  1.52
MAs MA(5) :  2.4 MA(20) :  2.38
MA(100) :  2.77 MA(250) :  2.29
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  64.5 D(3) :  57.3
RSI RSI(14): 41.1
52-week High :  4.32 Low :  0.62
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ TSHA ] has closed below upper band by 43.1%. Bollinger Bands are 62.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.46 - 2.48 2.48 - 2.49
Low: 2.18 - 2.2 2.2 - 2.21
Close: 2.27 - 2.29 2.29 - 2.31
Company Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Headline News

Wed, 17 Jul 2024
FY2024 Earnings Estimate for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Issued By Cantor Fitzgerald - MarketBeat

Wed, 17 Jul 2024
FY2024 EPS Estimates for Taysha Gene Therapies, Inc. Lifted by Analyst (NASDAQ:TSHA) - American Banking and Market News

Fri, 05 Jul 2024
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Thu, 27 Jun 2024
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37% - Simply Wall St

Wed, 26 Jun 2024
Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today? - InvestorPlace

Wed, 26 Jun 2024
Taysha Gene Therapies: TSHA-102 Gene Therapy Improves Quality of Life in Patients with Rett Syndrome - 2 Minute Medicine

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 201 (M)
Shares Float 110 (M)
Held by Insiders 17.2 (%)
Held by Institutions 69.9 (%)
Shares Short 14,720 (K)
Shares Short P.Month 17,040 (K)
Stock Financials
EPS -0.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.28
Profit Margin 0 %
Operating Margin -713.3 %
Return on Assets (ttm) -38.9 %
Return on Equity (ttm) -606.7 %
Qtrly Rev. Growth -27.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.07
EBITDA (p.s.) -0.39
Qtrly Earnings Growth 0 %
Operating Cash Flow -73 (M)
Levered Free Cash Flow -57 (M)
Stock Valuations
PE Ratio -2.94
PEG Ratio 0
Price to Book value 7.89
Price to Sales 32.56
Price to Cash Flow -6.35
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android